MétaCan
Menu
Back to cohort

Resveratrol Protects Against Angiotensin II‐Induced Cellular Hypertrophy through Inhibition of CYP1B1/Mid‐Chain Hydroxyeicosatetraenoic Acid Mechanism

2019· article· en· W3176544105 on OpenAlexafffundabout
Sherif M. Shoieb, Ayman O.S. El‐Kadi

Bibliographic record

VenueThe FASEB Journal · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicEicosanoids and Hypertension Pharmacology
Canadian institutionsUniversity of Alberta
FundersCanadian Institutes of Health Research
KeywordsHydroxyeicosatetraenoic acidResveratrolChemistryMuscle hypertrophyEndocrinologyInternal medicineMetaboliteAngiotensin IICYP1B1PharmacologyCytochrome P450BiochemistryBiologyReceptorArachidonic acidMetabolismMedicineEnzyme

Abstract

fetched live from OpenAlex

Objective Cytochrome P450 1B1 (CYP1B1) and its associated cardiotoxic mid‐chain hydroxyeicosatetraenoic acid (HETEs) metabolites have been reported to directly contribute to the development of cardiac hypertrophy. Resveratrol (RESV) is naturally occurring and commercially available polyphenol that possess beneficial effects in wide array of cardiovascular diseases. Several reports have shown the capacity of RESV to treat cardiac hypertrophy, myocardial infarction and heart failure. However, the underlying mechanisms, responsible for RESV beneficial effects, are not fully elucidated. Since RESV is a well‐known CYP1B1 inhibitor, the purpose of this study is to investigate whether RESV protects against angiotensin II (Ang II)‐induced cellular hypertrophy through inhibition of CYP1B1/mid‐chain HETEs mechanism. Methods Human ventricular cardiomyocytes RL‐14 and rat cardiomyoblast H9c2 cells were treated with vehicle or 10 μM Ang II in the absence and presence of 2, 10 or 50 μM RESV for 24 h. Thereafter, the level of mid‐chain HETEs was determined using liquid chromatography–mass spectrometry (LC/MS). Hypertrophic markers and CYP gene expression and protein levels were measured using real‐time PCR and Western blot analysis, respectively. Results Our results demonstrated that RESV, at concentrations of 10 and 50 μM, was able to protect against Ang‐II‐induced cellular hypertrophy as evidenced by a substantial inhibition of hypertrophic markers, β‐myosin heavy chain (MHC)/α‐MHC and atrial natriuretic peptide (ANP). Ang II significantly induced the protein expression of CYP1B1 and increased the metabolite formation rate of its associated mid‐chain HETEs namely 5‐, 8‐, 9‐, 12‐ and 15‐HETE in both cell lines. Interestingly, the protective effect of RESV, at concentrations 10 and 50 μM, was associated with a significant decrease of CYP1B1 protein expression and mid‐chain HETEs to nearly control levels. Conclusion Our results provided the first evidence that RESV protects against Ang II‐induced cellular hypertrophy, at least in part, through CYP1B1/mid‐chain HETEs‐dependent mechanism. Support or Funding Information This work was supported by a grant from the Canadian Institutes of Health Research [Grant 106665] to A.O.S.E. S.M.S. is the recipient of Antoine Noujaim Graduate Scholarship in Pharmaceutical Sciences. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.226
Teacher spread0.213 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2019
Admission routes3
Has abstractyes

Explore more

Same venueThe FASEB JournalSame topicEicosanoids and Hypertension PharmacologyFrench-language works237,207